Description: Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.
Home Page: www.corline.se
Lefflersgatan 5
Uppsala,
754 50
Sweden
Phone:
46 18 71 30 90
Officers
| Name | Title |
|---|---|
| Dr. Henrik Nittmar Ph.D. | Chief Exec. Officer |
| Prof. Gunnar Tufveson | Chief Medical Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 316.6667 |
| Price-to-Book MRQ: | 2.1987 |
| Price-to-Sales TTM: | 6.4415 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |